Antisense Oligonucleotides for Prion Disease

Anne Smith, Executive Director, Clinical Development at Ionis Pharmaceuticals

Anne Smith, PhD, is an Executive Director of Clinical Development at Ionis Pharmaceuticals, a California-based biotechnology company focused on RNA-targeting therapeutics. She is responsible for shepherding promising therapies from the research stage through clinical trials.  She specializes in neurology drug development and leads teams working in multiple disease areas. Anne is passionate about developing treatments for underserved patients and is thrilled to be leading Ionis’ prion development program. She will be presenting on antisense oligonucleotide targeting of PRNP mRNA as potential treatment for prion disease.

[dianescalzo]

Thank you for this amazingly hopeful presentation for all who are affected by a Prion Disease 💜

[shannonshannon]

Thank you so much for all that are affected by Prion Diseases and working toward helping others and my family.